Drug Profile

ANPD 001

Alternative Names: A9-line dopamine neuron therapy - Aspen Neuroscience; ANPD-001

Latest Information Update: 15 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Aspen Neuroscience
Class Induced pluripotent stem cell therapies
Mechanism of Action Dopaminergic cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase I/II Parkinson's disease

Most Recent Events

07 May 2025 Efficacy and adverse events data from a phase I/IIa ASPIRO trial in Parkinson's disease released by Aspen Neuroscience
13 Jan 2025 Adverse events data from a phase I/IIa ASPIRO trial in Parkinson's disease released by Aspen Neuroscience
15 May 2024 Aspen Neuroscience completes enrolment in phase-I/II clinical trial in Parkinson's disease (Treatment-experienced) in USA (Parenteral) (NCT06344026)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com